DrugPatentWatch Database Preview
LIPIODOL Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Lipiodol, and when can generic versions of Lipiodol launch?
Lipiodol is a drug marketed by Guerbet and is included in one NDA.
The generic ingredient in LIPIODOL is ethiodized oil. There is one drug master file entry for this compound. Additional details are available on the ethiodized oil profile page.
Summary for LIPIODOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 32 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LIPIODOL |
| DailyMed Link: | LIPIODOL at DailyMed |
Generic Entry Opportunity Date for LIPIODOL
Generic Entry Date for LIPIODOL*:
Constraining patent/regulatory exclusivity:
SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC) NDA:
Dosage:
OIL;INTRALYMPHATIC, INTRAUTERINE |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LIPIODOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Early Phase 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| University Hospital, Strasbourg, France | Phase 4 |
US Patents and Regulatory Information for LIPIODOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet | LIPIODOL | ethiodized oil | OIL;INTRALYMPHATIC, INTRAUTERINE | 009190-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
